Aerie Pharmaceuticals, Inc. AERI
At closeNov 18, 2022, 4:00 PM EST
52-week range unavailable
- Market cap
- 753.62M
- Revenue (ttm)
- 213.94M
- Profit margin
- -17.09%
- Shares out
- 49.42M
- Forward P/E
- -13.86
- Volume
- 1.22M
- Open
- 15.24
- Previous close
- 15.25
- Day's range
- 15.24 – 15.25
- Beta
- -0.06
- Analysts
- Hold
- Price target
- 15.35 (+0.7%)
- Earnings date
- Nov 3, 2022
6M +8.11 (+113.59%)
Key statistics
- Enterprise value
- 918.14M
- PEG ratio
- 0.07
- Price / sales
- 3.52
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 23.30%
- Free cash flow
- 1.83M
- Total cash
- 172.46M
- Total debt
- 336.99M
- Return on equity
- 0.00%
- Short % of float
- 3.13%
- 50-day average
- 15.19
- 200-day average
- 10.24
Analyst view
Consensus: hold
- Target (low)
- 6.00
- Target (mean)
- 15.35
- Target (high)
- 25.00
- Strong buy3
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 3, 2022
Expected Nov 3, 2022. Consensus EPS estimate -0.43.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2022 | Sep 1, 2022 | -0.42 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.52 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -0.65 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -0.68 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -0.62 | — | — | — |
| Aug 4, 2021 | Jun 1, 2021 | -0.65 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 29, 2022 | Citigroup | down | Buy | Neutral |
| Aug 24, 2022 | Truist Securities | down | Buy | Hold |
| Aug 24, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 23, 2022 | Stifel | down | Buy | Hold |
| Aug 23, 2022 | Needham | down | Buy | Hold |
| Aug 23, 2022 | Cantor Fitzgerald | down | Overweight | Neutral |
About Aerie Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- aeriepharma.com
News
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business 
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates 
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results 
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains 
5 Small Hidden Gems Flying High Despite Market's Bloodbath 
5 Stocks to Bet on in an Innovation-Driven Drug Industry 
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year? 
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI 
Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year? 
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
Your note
Sign in to keep a note on AERI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CALABRESE JEFFREY | Officer | Stock Award(Grant) | Jun 30, 2022 | 19,295 |
| CROARKIN RICHARD | Director | Stock Award(Grant) | Jun 8, 2022 | 16,095 |
| DU TOIT MICHAEL | Director | Stock Award(Grant) | Jun 8, 2022 | 16,095 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | Jun 8, 2022 | 13,491 |
| KOPCZYNSKI CASEY C | Officer | Stock Award(Grant) | Mar 17, 2022 | 280,244 |
| LANG PETER FREDERICK | Chief Financial Officer | Stock Award(Grant) | Mar 17, 2022 | 46,297 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 9.82% | 4,855,005 | 74.04M | Sep 29, 2022 |
| Blackrock Inc. | 7.17% | 3,544,947 | 54.06M | Sep 29, 2022 |
| Vanguard Group, Inc. (The) | 4.94% | 2,441,120 | 37.23M | Sep 29, 2022 |
| UBS Group AG | 4.87% | 2,405,832 | 36.69M | Sep 29, 2022 |
| Jefferies Group LLC | 4.78% | 2,361,000 | 36.01M | Sep 29, 2022 |
| Water Island Capital, LLC | 4.21% | 2,082,516 | 31.76M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.92% | 1,445,441 | 22.04M | Jun 29, 2022 |
| Arbitrage Fund | 2.30% | 1,136,386 | 17.33M | Aug 30, 2022 |
| iShares Russell 2000 ETF | 2.11% | 1,044,068 | 15.92M | Sep 29, 2022 |
| Vanguard Extended Market Index Fund | 1.32% | 650,497 | 9.92M | Jun 29, 2022 |
| Columbia Fds Var Ser Tr II-Columbia Var Port-Overseas Core Fd | 1.09% | 540,033 | 8.24M | Jun 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 0.94% | 463,978 | 7.08M | Oct 30, 2022 |